НОВЫЕ ВОЗМОЖНОСТИ В ТЕРАПИИ БЕСПЛОДИЯ ПРИ ПРЕЖДЕВРЕМЕННОЙ НЕДОСТАТОЧНОСТИ ЯИЧНИКОВ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В обзоре представлены широкомасштабные мировые исследования по использованию андрогенов у больных с различными стадиями старения яичников, а также изложены все современные патогенетические механизмы, объясняющие положительные конечные результаты использования этой группы гормональных средств.

Полный текст

Доступ закрыт

Об авторах

Нигяр Новруз кызы ШАМИЛОВА

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: n_shamilova@oparina4.ru
аспирант отделения гинекологической эндокринологии 117997, Россия, Москва, ул. Академика Опарина д. 4

Лариса Андреевна МАРЧЕНКО

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: l_marchenko@oparina4.ru
доктор медицинских наук, профессор, ведущий научный сотрудник отделения гинекологической эндокринологии 117997, Россия, Москва, ул. Академика Опарина д. 4

Г. И ТАБЕЕВА

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Москва, Россия

Список литературы

  1. Практические рекомендации. Ведение женщин в пери-и постменопаузе. М.: ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова»; 2010: 32-3.
  2. Anderiesz C., Trounson A.O. The effect of testosterone on the maturation and development capacity of murine oocytes in vitro. Hum. Reprod. 1995; 10: 2377-81.
  3. Andux S., Ellis R.E. Apoptosis maintains oocyte quality in aging Caenorhabditis elegans females. PLoS Genet. 2008; 4(12): e1000295.
  4. Barad D., Gleicher N. Effect of dehydroepinadrosterone on oocytes and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 2006; 21: 2845-9.
  5. Barad D.H., Brill H., Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet. 2007; 24: 629-34.
  6. Barad D.H., Gleicher N. Increased oocytes production after treatment with dehydroepiandrosterone. Fertil. Steril. 2005; 84: 756; e1-3.
  7. Barad D.H., Weghofer A., Gleicher N. Comparing anti-Mullerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil. Steril. 2009; 91(Suppl. 4): 1553-5.
  8. Broekmans F.J., Soules M.R., Fauser B.C. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev. 2009; 30: 465-93.
  9. Buster J.E. Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone precursor replacement therapy (HPRT). Menopause. 2009; 16(5): 858-9.
  10. Casson P.R., Santoro N., Elkind-Hirsch K., Carson S.A., Hornsby P.J., Abraham G., Buster J.E. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil. Steril. 1998; 70: 107-10.
  11. Coccia M.E., Rizzello F. Ovarian reserve. Ann. N. Y. Acad. Sci. 2008; 1127: 27-30.
  12. Conway G.S., Kaltsas G., Patel A., Davies M.C., Jacobs H.S. Characterization of idiopathic premature ovarian failure. Fertil. Steril. 1996; 65(2): 337-41.
  13. Eppig J.J., Freter R.R., Ward Bailey P.F., Schultz R.M. Inhibition of oocyte maturation in the mouse: participation of cAMP, steroid hormone, and a putative maturation-inhibitory factor. Dev. Biol. 1983; 100: 39-49.
  14. Faddy M.J., Gosden R.G. A mathematical model of follicle dynamics in the human ovary. Hum. Reprod. 1995; 10(4): 770-5.
  15. Fraisse T., Ibecheole V., Streuli I., Bischof P., de Ziegler D. Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil. Steril. 2008; 89(3): 711-29.
  16. Gleiche rN., Ryan E., Weghofer A., Blanco-Mejia S., Barad D.H. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod. Biol. Endocrinol. 2009; 7: 108.
  17. Gleicher N., Weghofer A., Barad D. Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertil. Steril. 2007; 88(Suppl. 1) :S232.
  18. Gleicher N., WeghoferA., Barad D.H. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good livebirth chances in women with severely diminished ovarian reserve. Fertil. Steril. 2010; 94(7): 2824-7.
  19. Gleicher N., Weghofer A., Barad D.H. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod. Biol. Endocrinol. 2010; 8: 140.
  20. Gleicher N., Barad D.H. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 2011; 9: 67.
  21. Hansen K.R., Knowlton N.S., Thyer A.C., Charleston J.S., Soules M.R., Klein N.A. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum. Reprod. 2008; 23(3): 699-708.
  22. Heijnen E.M., Eijkemans M.J., Hughes E.G., Laven J.S., Macklon N.S., Fauser B.C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update. 2006; Hodges C.A., Ilagan A., Jenninger D., Keri R., Nilson J., Hunt P.A. Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Hum. Reprod. 2002; 17: 1171-80.
  23. La Marca A., Marzotti S., Brozzetti A., Stabile G., Artenisio A.C., Bini V. et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J. Clin. Endocrinol. Metab. 2009; 94(10): 3816-23.
  24. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Serum steroid levels during 12week intravaginal dehydroepiandrosterone administration. Menopause. 2009; 16: 897-906.
  25. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog. Brain Res. 2010; 182: 97-148.
  26. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009; 16: 907-22.
  27. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Effect on intravaginal dehydroepi-androsterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009; 16: 923-31.
  28. Labrie F., Bélanger A., Bélanger P., Berube R., Martel C., Cusan L. et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J. Steroid Biochem. Mol. Biol. 2007; 103(2): 178-88.
  29. Labrie F., Bélanger A., Cusan L., Séguin C., Pelletier G., Kelly P.A. et al. Antifertility effects of LHRH agonists in the male. J. Androl.1980; 1: 209-28.
  30. Labrie F., Bélanger A., Luu-The V., Labrie C., Simard J., Cusan L., et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging. Steroids. 1998; 63(5-6): 322-8.
  31. Labrie F., Dupont A., Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita V.T., Hellman S., Rosenberg S.A., eds. Important advances in oncology. Philadelphia: J. B. Lippincott; 1985: 193-217.
  32. Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S. -X. et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 2003; 24(2): 152-82.
  33. Labrie F., Luu-The V., Lin S.-X., Simard J., Labrie C. Role of 17b-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endoclinol. Metab. 2000; 11(10): 421-7.
  34. Lenie S., Smitz J. Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol. Reprod. 2009; 80:685-95.
  35. Luchetti C.G., Solano M.E., Sander V., Arcos M.L., Gonzalez C., Di Girolamo G. et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J. Reprod. Immunol. 2004; 64: 59-74.
  36. Mamas L., Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil. Steril. 2009; 91: 644-6.
  37. Nybo Andersen A.M., Wohlfahrt J., Christens P., Olsen J., Melbye M. Maternal age and fetal loss: population register linkage study. Br. Med. J. 2000; 320:1708-12.
  38. Patrizio P., Leong M. Survey: Poor responders: How to define, diagnose and treat? http://www.ivf-worldwide.com/survey/ survey-poor-responders.htm.
  39. Qiao J., Feng H.L. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum. Reprod. Update. 2010; 17:17-33.
  40. Sander V., Lucchetti C.G., Solano M.E., Elia E., Di Girolamo G., Gonzalez C., Motta A.B. Role of the N,N’-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 2006; 131: 591-602.
  41. Schultz R.M., Montgomery R.R., Ward-Bailey P.F., Eppig J.J. Regulation of oocyte maturatation in the mouse: possible roles of intercellular communication, cAMP, and testosterone. Dev. Biol. 1983; 95: 294-304.
  42. Shi X., Li N., Liao C., Shu Q., Zhu F. Glucocorticoid or androgen for autoimmune premature ovary failure in mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009; 34: 576-81.
  43. Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., Cenazzani A.R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003; 144(8): 3449-55.
  44. Smith D.M., Tenney D.Y. Effects of steroids on mouse oocyte maturation in vitro. J. Reprod. Fertil. 1980; 60: 331-8.
  45. The 2008 position statement of the North American Menopause Society (NAMS). 2008: 10-23.
  46. Tulandi N., Gelfand M.M. Androgens and reproductive aging. London; New York: Taylor and Francis Group. 2006; 179.
  47. Wallace W.H., Kelsey T.W. Human ovarian reserve from conception to the menopause. PLoS One. 2010; 5(1): e8772.
  48. Wiser A., Gonen O., Ghetler Y., Shavit T., Berkovitz A., Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 2010; 25: 2496-500.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах